Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...

AXSM : 52.66 (+1.68%)
Axsome Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

NEW YORK, NY / ACCESSWIRE / July 21, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are advised...

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ:AXSM). Such investors are advised...

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are advised to contact at   or...

AXSM : 52.66 (+1.68%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Axsome Therapeutics, Inc. (AXSM) Investigation

NEW YORK, NY / ACCESSWIRE / July 15, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Axsome Therapeutics, Inc. ('Axsome" or 'the Company') (NASDAQ:AXSM)....

AXSM : 52.66 (+1.68%)
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag

The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.

PFE : 42.10 (+0.69%)
JAZZ : 173.71 (+0.26%)
AXSM : 52.66 (+1.68%)
HRMY : 25.68 (-3.89%)
Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021

Axsome to host conference call and webcast on Monday, August 9, 2021 at 8:00 AM Eastern Time

AXSM : 52.66 (+1.68%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM).  Such investors are advised to contact at  ...

AXSM : 52.66 (+1.68%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 119.81 (+0.24%)
ACRX : 1.1900 (-1.65%)
ACOR : 3.96 (-7.69%)
AXSM : 52.66 (+1.68%)
BAYRY : 14.9200 (-1.33%)
BDRFF : 119.7000 (unch)
BDSI : 3.64 (+0.55%)
BMY : 67.49 (-0.30%)
COLL : 24.76 (+0.61%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3600 (-1.45%)
EGLT : 0.0315 (-63.37%)
LLY : 243.58 (+0.15%)
FLXN : 6.14 (-1.13%)
GLPG : 60.37 (+0.48%)
HRTX : 12.24 (-2.47%)
KMPH : 10.76 (+0.09%)
MRK : 77.85 (+0.79%)
MESO : 7.04 (-1.68%)
NKTR : 15.91 (-2.03%)
NVS : 91.32 (+0.40%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.10 (+0.69%)
REGN : 581.01 (+0.56%)
VRX.TO : 30.80 (-3.33%)
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.

RGEN : 226.38 (+9.89%)
ADPT : 35.42 (-3.80%)
AXSM : 52.66 (+1.68%)
BNTX : 284.00 (-0.79%)
Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia

Submission anticipated in 4Q 2022

AXSM : 52.66 (+1.68%)
Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AXSM : 52.66 (+1.68%)
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 119.81 (+0.24%)
ACRX : 1.1900 (-1.65%)
ACOR : 3.96 (-7.69%)
AXSM : 52.66 (+1.68%)
BAYRY : 14.9200 (-1.33%)
BDRFF : 119.7000 (unch)
BDSI : 3.64 (+0.55%)
BMY : 67.49 (-0.30%)
COLL : 24.76 (+0.61%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3600 (-1.45%)
EGLT : 0.0315 (-63.37%)
LLY : 243.58 (+0.15%)
FLXN : 6.14 (-1.13%)
GLPG : 60.37 (+0.48%)
HRTX : 12.24 (-2.47%)
KMPH : 10.76 (+0.09%)
MRK : 77.85 (+0.79%)
MESO : 7.04 (-1.68%)
NKTR : 15.91 (-2.03%)
NVS : 91.32 (+0.40%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.10 (+0.69%)
REGN : 581.01 (+0.56%)
VRX.TO : 30.80 (-3.33%)
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus

Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.

RGEN : 226.38 (+9.89%)
ADPT : 35.42 (-3.80%)
AXSM : 52.66 (+1.68%)
BNTX : 284.00 (-0.79%)
Axsome: Q1 Earnings Snapshot

NEW YORK (AP) _ Axsome Therapeutics Inc. (AXSM) on Monday reported a loss of $29.3 million in its first quarter.

AXSM : 52.66 (+1.68%)
Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern

AXSM : 52.66 (+1.68%)
Axsome Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Axsome Therapeutics, Inc. (NASDAQ:AXSM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 8:00...

AXSM : 52.66 (+1.68%)
Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)

Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AXSM : 52.66 (+1.68%)
Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month

Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month, by raising awareness of and supporting people living...

AXSM : 52.66 (+1.68%)

Barchart Exclusives

Rising Energy Prices Increase Production Costs - This Week In Metals
This week we look at China's efforts to keep a lid on metals prices and how rising energy prices are making it more expensive to mine and refine the metals that are the building blocks for infrastructure building and rebuilding. Q2 earnings for Steel Dynamics and Nucor exceeded expectations. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar